Gilead Withdraws Trodelvy in Bladder Cancer Amid Trial Setbacks

Gilead Sciences has withdrawn Trodelvy for bladder cancer following a failed TROPiCS-04 trial, which showed no survival advantage over chemotherapy[1][2]. Originally granted accelerated approval in 2021, Trodelvy's efficacy in shrinking tumors was undermined by these results[2]. This decision follows FDA discussions and echoes a broader trend of withdrawing conditional approvals after negative trial outcomes, such as seen with other companies like GSK and Takeda[1]. Despite this setback, Trodelvy remains approved for breast cancer and is projected to maintain significant sales growth in that area[1][2].